Qiagen N.V. (QGEN) is a Medical - Diagnostics & Research company in the Healthcare sector, currently trading at $41.76. It has a SharesGrow Score of 74/100, indicating a above average investment profile with 3 out of 7 criteria passed.
SharesGrow calculates the intrinsic value of QGEN = $57.39 (+37.4% from the current price, the stock appears undervalued). Analyst consensus target is QGEN = $54 (+30.1% upside).
Valuation: QGEN trades at a trailing Price-to-Earnings (P/E) of 19.8 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 1.94.
Financials: revenue is $2.1B, -0.6%/yr average growth. Net income is $425M, growing at +104.5%/yr. Net profit margin is 20.3% (strong). Gross margin is 61.8% (-2.9 pp trend).
Balance sheet: total debt is $1.7B against $3.8B equity (Debt-to-Equity (D/E) ratio 0.44, conservative). Current ratio is 3.9 (strong liquidity). Debt-to-assets is 26.3%. Total assets: $6.3B.
Analyst outlook: 12 / 29 analysts rate QGEN as buy (41%) — mixed sentiment.
SharesGrow 7-Criteria breakdown: Value 59/100 (Partial), Growth 58/100 (Partial), Past 100/100 (Pass), Health 100/100 (Pass), Moat 65/100 (Partial), Future 52/100 (Partial), Income 85/100 (Pass).
